Tarsus Reports Q3 2026 Net Product Sales Growth of 64% Driven by XDEMVY
Tarsus reported strong third-quarter 2026 financial results, highlighted by net product sales of $194.6 million, a 64% increase year-over-year. This growth was primarily driven by increased volume and improved gross-to-net discounts for its flagship product, XDEMVY, which has now surpassed $1 billion in cumulative sales within three years of launch. The company's net loss per share widened to $(14.40) compared to $(0.30) last year, a figure heavily impacted by one-time acquisition charges related to the Alkeus deal. Despite this, Tarsus maintains a strong liquidity position with $309.6 million in cash and equivalents, supporting its expanded clinical pipeline including TP-04, TP-05, and IRX-101.
Tickers: $TARS
Topics: Direct-to-Consumer investment Gross Margin Net Product Sales XDEMVY sales guidance
Read the full article at Motley Fool
Part of the story Crane NXT Reports Q3 2026 Results with Growth Driven by Antares Vision Acquisition (10 articles)